FDA approves two oral therapies to treat gonorrhea
The US Food and Drug Administration (FDA) on Friday announced it has approved two new oral medicines to treat a common sexually transmitted infection called gonorrhea.
The FDA approved Entasis Therapeutics’, a subsidiary of Innoviva Specialty Therapeutics’ (Nasdaq: INVA), Nuzolvence (zoliflodacin) granules that dissolve in water. This medicine can treat uncomplicated urogenital gonorrhea in adults and children 12 years and older who weigh at least 77 pounds.
The FDA also approved UK pharma major GSK’s (LSE: GSK) Blujepa (gepotidacin) oral tablets for the same condition in patients 12 years and older who weigh at least 99 pounds. This medicine is for patients who have few or no other treatment choices because of limited clinical safety data. Blujepa was first approved in March 2025 to treat urinary tract infections.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze